Vertex Pharmaceuticals (VRTX) stock is sliding after the company said it won't advance its pain treatment into the next phase ...

Shares of Kyndryl sank after the company recorded flat revenue in the latest completed quarter, missing analyst targets. The stock was down 19% at $29.82 in early trading. Shares are now in negative ...

Kyndryl Holdings (NYSE:KD) shares sank 16% during early market trading on Tuesday after its first quarter fiscal 2026 financial results demonstrated a slight revenue decline in constant currency.

Stock futures were rising early Tuesday as markets continued to gain on the back of improving odds for a September rate ...